Burkitt Lymphoma — Trials

Burkitt Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 27
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04034446	CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)	terminated	Early Phase 1	2	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	1	Jun 3, 2025	clinicaltrials

Data updated 22 days agoSource updated Jun 3, 2025source: clinicaltrials